GlassScriptPhysician profile
Matthew G Fox
NPI 1780644849
$4,406.60
in general payments reported to CMS, 2019-2025
27 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $302 · 2021: $425 · 2023: $754 · 2024: $936 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $791.76 | 2019-2025 | |
| Abbvie INC. | $580.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $415.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $393.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $347.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $251.83 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $250.88 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.37 | 2019-2025 | Jardiance, Trijardy Xr, Tradjenta |
| Phathom Pharmaceuticals, INC. | $159.54 | 2024-2025 | Voquezna |
| Allergan, INC. | $145.32 | 2019-2020 | |
| Astellas Pharma US INC | $103.90 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.04 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $80.47 | 2019-2025 | Shingrix, Bexsero, Menveo |
| Merck Sharp & Dohme LLC | $65.15 | 2019-2024 | Vaxelis, Gardasil 9, Capvaxive |
| Abbott Laboratories | $64.05 | 2023-2025 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.10 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $62.91 | 2021 | |
| Sanofi Pasteur INC. | $62.60 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.85 | 2019-2023 | |
| Dynavax Technologies Corporation | $57.51 | 2024-2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $51.73 | 2019-2024 | Ajovy |
| Xeris Pharmaceuticals, INC. | $18.50 | 2024 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $15.01 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.45 | 2019 | |
| Axsome Therapeutics, INC. | $13.30 | 2024 | Auvelity |
| Shire North American Group INC | $12.65 | 2019 | |
| Genentech USA, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.